MPM has collected three China drugs for its ‘best of both worlds’ strategy

Ansbert Gadicke, managing partner at MPM BioImpact and executive chair of K2 April 29, 2026 07:00 AM EDT StartupsDealsChina MPM has col­lect­ed three Chi­na drugs so far for its ‘best of both worlds’ strat­e­gy Kyle LaHucik Biotech Correspondent MPM BioIm­pact, a lead­ing biotech in­vestor, is go­ing all in on its strat­e­gy to take Chi­na-born drugs to the glob­al stage. Over the past year … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER